LG Chem, a leading chemical company based in South Korea, and Yifan Pharmaceutical Co., Ltd (SHE: 002019) from China, have announced the market launch of Hyruan ONE (sodium hyaluronate) in China for the treatment of knee osteoarthritis. Hyruan ONE, originally developed by LG Chem, is a single-dose preparation designed to serve as a temporary replacement and supplement for joint fluid. The product utilizes viscoelastic supplementary therapy to restore the histophysiology and rheological state of pathological joints. This launch follows regulatory approval received in April 2023.
Yifan entered into a 10-year licensing agreement with LG Chem in December 2017, securing exclusive rights to the product in China and Australia. Yifan also took on the responsibility for regulatory filing and conducting clinical trials. According to sources, the successful launch is the result of year-long negotiations with the National Healthcare Security Administration (NHSA), leading to the inclusion of LG Chem’s drug in the National Reimbursement Drug List.- Flcube.com
